A phase i trial of deep brain stimulation of memory circuits in Alzheimer's disease

Annals of Neurology

Volumn 68, Issue 4, 2010, Pages 521-534

  Laxton, Adrian W ^a   Tang Wai, David F ^b,e   McAndrews, Mary Pat ^c   Zumsteg, Dominik ^d   Wennberg, Richard ^e   Keren, Ron ^b   Wherrett, John ^b,e   Naglie, Gary ^b   Hamani, Clement ^b   Smith, Gwenn S ^f   Lozano, Andres M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF TORONTO   (Canada)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN FORNIX; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ENTORHINAL CORTEX; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HIPPOCAMPUS; HOSPITAL DISCHARGE; HUMAN; HYPOTHALAMUS; MALE; MEMORY; NERVE CONDUCTION; NEUROPHYSIOLOGY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARDIZATION; TEMPORAL LOBE; BRAIN; BRAIN MAPPING; ELECTROENCEPHALOGRAPHY; FOLLOW UP; FRONTAL LOBE; MEMORY DISORDER; METHODOLOGY; MIDDLE AGED; NERVE TRACT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; TIME;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; BRAIN MAPPING; CHOLINESTERASE INHIBITORS; DEEP BRAIN STIMULATION; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; HYPOTHALAMUS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MIDDLE AGED; NEURAL PATHWAYS; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 78049501333     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22089     Document Type: Article

References (64)

1. Querfurth HW, LaFerla FM., Alzheimer's disease. N Engl J Med 2010; 362: 329 344.
2. Palop JJ, Mucke L., Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin? Neuromolecular Med 2010; 12: 48 55.
3. Sperling RA, Dickerson, BC, Pihlajamaki M, et al. functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010; 12: 27 43.
4. Petersen RC, Jack CR Jr., Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment. Clin Pharmacol Ther 2009; 86: 438 441.
5. Risacher SL, Saykin AJ, West JD, et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009; 6: 347 361.
6. Smith GS, de Leon MJ, George AE, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications. Arch Neurol 1992; 49: 1142 1150.
7. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85 94.
8. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752 758.
9. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306 319.
10. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132 (pt 5): 1310 1323.
11. Fripp J, Bourgeat P, Acosta O, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008; 43: 430 439.
12. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709 7917.
13. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216 223.
14. Engler H, Forsberg A, Almkvist O, et al. A Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856 2866.
15. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 355 365.
16. Andrews-Hanna JR, Snyder AZ, Vincent JL, et al. Disruption of large-scale brain systems in advanced aging. Neuron 2009; 56: 924 935.
17. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178 188.
18. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci USA 2001; 98: 676 682.
19. Greicius MD, Srivastava G, Reiss AL, Menon V., Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004; 101: 4637 4642.
20. Buckner RL, Andrews-Hanna JR, Schacter DL., The brain's default network: anatomy, function, and relevance to disease [review]. Ann N Y Acad Sci 2008; 1124: 1 38.
21. Miller SL, Celone K, DePeau K, et al. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci USA 2008; 105: 2181 2186.
22. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009; 62: 42 52.
23. Davis KD, Kiss ZHT, Luo L, et al. Phantom sensations generated by thalamic microstimulation. Nature 1998; 391: 385 387.
24. Lang AE, Lozano AM., Parkinson's disease. Part II: medical progress. N Engl J Med 1998; 339: 1130 1143.
25. Davis K, Taub E, Houle S, et al. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med 1997; 3: 671 674.
26. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997; 42: 292 299.
27. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352: 459 467.
28. Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004; 56: 290 294.
29. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651 660.
30. Lozano AM, Mayberg H, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64: 461 467.
31. Hamani C, McAndrews MP, Cohn M, et al. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol 2008; 63: 119 123.
32. Powell TPS, Guillery RW, Cowan WM., A quantitative study of the fornix-mammillothalamic system. J Anat 1957; 91: 419 432.
33. Tsivilis D, Vann SD, Denby C, et al. A disproportionate role for the fornix and mammillary bodies in recall versus recognition memory. Nat Neurosci 2008; 7: 834 842.
34. Wilson CR, Baxter MG, Easton A, Gaffan D., Addition of fornix transsection to frontal-temporal disconnection increases the impairment in object-in-place memory in macaque monkeys. Eur J Neurosci 2008; 27: 1814 1822.
35. Browning PG, Gaffan D, Croxson PL, Baxter MG., Severe scene learning impairment, but intact recognition memory, after cholinergic depletion of inferotemporal cortex followed by fornix transection. Cereb Cortex 2010; 20: 282 293.
36. Vann SD, Tsivilis D, Denby CE, et al. Impaired recollection but spared familiarity in patients with extended hippocampal system damage revealed by 3 convergent methods. Proc Natl Acad Sci USA 2009; 106: 5442 5447.
37. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1983; 34: 939 944.
38. Morris JC., The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1992; 43: 2412b 2414b.
39. Folstein MF, Folstein SE, McHugh PR., Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189 198.
40. Rosen WG, Mohs RC, Davis KL., A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 41: 1356 1364.
41. Ito K, Ahadieh S, Corrigan B, et al. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 2010; 6: 39 53.
42. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 1: 390 396.
43. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (suppl 2): S22 S32.
44. Logsdon RG, Gibbons LE, McCurry SM, Teri L., Assessing quality of life in older adults with cognitive impairment. Psychosom Med 2002; 64: 510 519.
45. Pascual-Marqui RD., Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details. Methods Find Exp Clin Pharmacol 2002; 24 (suppl D): 5 12.
46. Hamacher K, Coenen H, Stöcklin G., Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235 238.
47. Lemaire C, Damhaut B, Lauricella C, et al. Fast [18F]FDG synthesis by alkaline hydrolysis on a low polarity solid phase support. J Labelled Comp Radiopharm 2002; 45: 435 447.
48. Takikawa S, Dhawan V, Spetsieris P, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993; 188: 131 136.
49. Smith G, Kramer E, Hermann C, et al. Cholinergic modulation of serotonin function measured with PET in Alzheimer's disease. Brain 2009; 132 (pt 2): 392 401.
50. Mayeux R, Sano M., Treatment of Alzheimer's disease [review]. N Engl J Med 1999; 341: 1670 1679.
51. Vogel A, Mortensen EL, Hasselbalch SG, et al. Patient versus informant reported quality of life in the earliest phases of Alzheimer's disease. Int J Geriatr Psychiatry 2006; 12: 1132 1138.
52. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991; 1: 103 116.
53. Seely WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007; 27: 2349 2356.
54. Zhou J, Greicius MD, Gennatas ED, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 2010; 133: 1352 1367.
55. Smith G, Kramer E, Hermann C, et al. Cholinergic modulation of serotonin function measured with PET in Alzheimer's disease. Brain 2009; 132 (pt 2): 392 401.
56. Tune L, Tiseo PJ, Leni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003; 11: 169 177.
57. Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008; 63: 621 631.
58. Stefanova E, Wal lA, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 2006; 113: 205 218.
59. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002; 159: 738 745.
60. Ranck JB Jr., Which elements are excited in electrical stimulation of mammalian central nervous system: a review. Brain Res 1975; 98: 417 440.
61. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551 555.
62. Toda H, Hamani C, Fawcett AP, et al. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg 2008; 108: 132 138.
63. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15: 331 337.
64. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119 1122.